Physician profile
John Edwin Bubser
NPI 1184763583
$746.80
in general payments reported to CMS, 2019-2025
13 companies · $15.58 in 2025
The $15.58 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $47.32 · 2021: $93.06 · 2022: $85.30 · 2023: $163 · 2024: $60.27 · 2025: $15.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $142.60 | 2023-2024 | Senza |
| Melinta Therapeutics, LLC | $124.97 | 2019 | |
| Smith+Nephew, INC. | $84.72 | 2021-2024 | Stravix |
| Musculoskeletal Transplant Foundation INC. | $78.11 | 2019 | |
| Organogenesis INC. | $62.72 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.40 | 2019-2020 | |
| Sandoz INC. | $38.38 | 2019 | |
| Mayne Pharma Commercial LLC | $35.91 | 2021 | |
| Convatec INC. | $35.42 | 2023 | |
| Paratek Pharmaceuticals, INC. | $30.75 | 2021-2025 | Nuzyra |
| Triad Life Sciences INC. | $28.85 | 2022 | |
| Averitas Pharma INC. | $21.96 | 2024 | Qutenza |
| Hikma Pharmaceuticals USA | $20.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bubser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.